文献速递血栓与止血

艾曲泊帕用于继发性免疫性血小板减少症临床实践

Use of eltrombopag for secondary immune thrombocytopenia in clinical practice.
PubMed 文献 · Br J Haematol · 2017-06-01

该研究回顾性评估87例继发性免疫性血小板减少症患者在日常临床实践中使用艾曲泊帕的疗效与安全性,44例(38%)出现血小板反应,其中40例(35%)为完全反应,中位起效时间15天,淋巴增殖性疾病相关ITP组反应率显著较低,43例(49.4%)发生不良事件,主要为1-2级。

要点

  • 87例继发性ITP患者中44例(38%)出现血小板反应,40例(35%)为完全反应
  • 中位起效时间15天(95%CI 7-28天),淋巴增殖性疾病相关ITP组起效更长
  • 淋巴增殖性疾病相关ITP组血小板反应率显著低于其他组,但持续反应无显著差异

核心结论

  • 在日常临床实践中,艾曲泊帕对继发于免疫和感染性疾病的非选择性ITP患者有效且耐受性良好
  • 淋巴增殖性疾病相关ITP组的反应率较低

研究设计与样本

  • 回顾性评估87例继发性ITP患者,其中46例继发于自身免疫综合征,23例继发于肿瘤性疾病亚型(淋巴增殖性疾病),18例继发于病毒感染

主要发现

  • 44例(38%)出现血小板反应,其中40例(35%)为完全反应
  • 中位起效时间15天(95%CI 7-28天),淋巴增殖性疾病相关ITP组更长
  • 淋巴增殖性疾病相关ITP组血小板反应率显著低于其他组
  • 达到反应后,各组持续反应无显著差异
  • 43例(49.4%)发生不良事件,主要为1-2级,最常见为肝胆实验室异常

临床怎么用

  • 原文未据此给出推荐

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Eltrombopag is a second-line treatment in primary immune thrombocytopenia (ITP). However, its role in secondary ITP is unknown. We evaluated the efficacy and safety of eltrombopag in secondary ITP in daily clinical practice. Eighty-seven secondary ITP patients (46 with ITP secondary to autoimmune syndromes, 23 with ITP secondary to a neoplastic disease subtype: lymphoproliferative disorders [LPDs] and 18 with ITP secondary to viral infections) who had been treated with eltrombopag were retrospectively evaluated. Forty-four patients (38%) had a platelet response, including 40 (35%) with complete responses. Median time to platelet response was 15 days (95% confidence interval, 7-28 days), and was longer in the LPD-ITP group. Platelet response rate was significantly lower in the LPD-ITP than in other groups. However, having achieved response, there were no significant differences between the durable response of the groups. Forty-three patients (49·4%) experienced adverse events (mainly grade 1-2), the commonest being hepatobiliary laboratory abnormalities. There were 10 deaths in this case series, all of which were related to pre-existing medical conditions. In routine clinical practice, eltrombopag is effective and well-tolerated in unselected patients with ITP secondary to both immune and infectious disorders. However, the response rate in LPD-ITP is low.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. González-López TJ, Alvarez-Román MT, Pascual C, et al. Use of eltrombopag for secondary immune thrombocytopenia in clinical practice. Br J Haematol. 2017. PMID: 28573819. doi:10.1111/bjh.14788

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。